Application Number	Re		plicant(s)/Patent under examination RIFFITHS ET AL		
Document Code - DISQ		Internal Docu		ument – DO NOT MAIL	
7					
TERMINAL DISCLAIMER	☑ APPROVED		☐ DISAPP	☐ DISAPPROVED	
Date Filed : April 16, 2007	This patent is subject to a Terminal Disclaimer				
Approved/Disapproved by:					
Henry D. Jefferson					

U.S. Patent and Trademark Office

PTO/SB/26 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)				
REJECTION OVER A "PRIOR" PATENT	78258-329549				
In re Application of: Gary L. Griffiths et al.					
Application No.: 10/066,782					
Filed: February 6, 2002					
For: Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug					
The owner*, Immunomedics. Inc, of					
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.					
Check either box 1 or 2 below, if appropriate.					
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.					
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.					
2.  The undersigned is an attorney or agent of record. Reg. No. 42,023					
MI H	4/16/07				
Signature	Date				
Richard A. Nakashima					
Typed or printed name					
	303-447-7728 Telephone Number				
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
*Statement_under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner Form PTO/SB/96 may be used for making this certification. See MPEP § 324.					

This collection of Information is required by 37 CFR 1.321. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.